Acromegaly Global Market Report 2024

The global acromegaly market has grown rapidly in recent years. It will grow from $1.79 billion in 2023 to $2.15 billion in 2024 at a compound annual growth rate (CAGR) of 19.8%. The growth in the historic period can be attributed to increasing prevalence of acromegaly therapeutics, growing awareness about acromegaly, government initiatives, demand for effective treatments.

The global acromegaly market is expected to see rapid growth in the next few years. It will grow to $4.17 billion in 2028 at a compound annual growth rate (CAGR) of 18.1%. The growth in the forecast period can be attributed to investments in research and development activities for acromegaly treatments, growing number of screening programs, rising healthcare spending, increasing demand for minimally invasive treatment options. Major trends in the forecast period include innovative treatments for acromegaly, development of targeted therapies for acromegaly, strong pipeline of drugs, advancements in treatment options, advanced personalized medicine.

The increasing incidence of hormonal diseases, including diabetes, is set to drive the growth of the acromegaly market in the foreseeable future. Hormonal diseases, also known as endocrine disorders, encompass medical conditions arising from the malfunction of the endocrine system. Diabetes stands as one of the most widespread and impactful hormonal diseases. Acromegaly, alongside other endocrine disorders, can be a consequence of the excessive production of specific hormones, such as growth hormone or cortisol. Furthermore, owing to the profound effect of elevated growth hormone levels on insulin synthesis, approximately 50% of individuals with acromegaly may develop insulin resistance or type 2 diabetes mellitus.For example, as of December 2021, data from the International Diabetes Federation, a US-based intergovernmental organization, revealed that diabetes affected 537 million adults aged 20-79 years in 2021. Projections indicate that this number will escalate to approximately 643 million individuals by 2030 and is expected to reach a staggering total of 783 million by 2045. Thus, the increasing prevalence of hormonal diseases is the driving force behind the growth of the acromegaly market.

The escalating prevalence of genetic abnormalities is poised to be a key driver for the future expansion of the acromegaly market. Genetic abnormalities, often known as genetic defects or genetic disorders, encompass alterations or mutations that manifest in the DNA sequence of an individual's genes and can lead to atypical features, functions, or characteristics. Acromegaly, a condition characterized by the overproduction of growth hormone (GH) by the pituitary gland, is frequently associated with noncancerous adenomas, which can occur sporadically or be linked to specific genetic abnormalities. For instance, as of February 2022, data from the World Health Organization (WHO), a Switzerland-based intergovernmental organization, indicated that congenital abnormalities contribute to the mortality of 240,000 newborns within the first 28 days of life annually. Additionally, an extra 170,000 children aged between 1 month and 5 years lose their lives due to congenital abnormalities, encompassing conditions like heart defects, neural tube defects, and Down syndrome. Consequently, the rising incidence of genetic abnormalities is poised to propel the acromegaly market forward.

The growth of the acromegaly market during the projected period is hampered by delayed diagnosis. The shortage of skilled healthcare professionals, particularly oncologists, poses a significant challenge for individuals afflicted with acromegaly. This dearth can result in delays in both diagnosis and treatment, elevating the risk of complications, and ultimately leading to diminished patient satisfaction. For instance, data from Frontiers Media SA in 2022 indicated that a substantial 22.6% of individuals dealing with acromegaly reported enduring a delay in their diagnosis. This delay often meant that more than a year elapsed between their initial medical consultation and the formal diagnosis of the condition. Consequently, delayed diagnosis remains a critical impediment to the growth of the acromegaly market.

The prominent companies in the acromegaly market are strategically focused on the development of inventive products and solutions to establish a competitive edge and maintain their market dominance. For example, in July 2021, Advanz Pharma Corp., a pharmaceutical company based in the United Kingdom, introduced Mytolac (lanreotide) in Germany. This marked the launch of the first generic lanreotide for the treatment of acromegaly, particularly for grade 1 and a subset of grade 2 gastroenteropancreatic neuroendocrine tumors. Lanreotide comes highly recommended for addressing acromegaly patients whose levels of circulating growth hormone (GH) and insulin-like growth factor-1 (IGF-1) remain abnormal even after undergoing surgery, radiation therapy, or other medical interventions. This strategic emphasis on innovation underscores how inventive solutions are propelling these companies to establish their dominance in the acromegaly treatment market.

In September 2021, Xeris Pharmaceuticals Inc., a pharmaceutical company based in the United States, completed the acquisition of Strongbridge Biopharma PLC for an undisclosed sum. This strategic move culminated in the amalgamation of Xeris and Strongbridge's operations, forming a new entity known as Xeris Biopharma Holdings. The merged entity, Xeris, is poised to become a pioneering force in the fields of endocrinology and neurology. It boasts a unique technology platform ideally positioned to address the unmet needs of the patients it serves. Strongbridge Biopharma PLC, a biopharmaceutical company based in the United States, had been dedicated to the development of pharmaceuticals designed to treat rare endocrine disorders, with a particular focus on conditions like acromegaly.

Major players in the acromegaly market are Pfizer Inc., Johnson & Johnson Private Limited, Merck & Co Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., AstraZeneca PLC, GlaxoSmithKline PLC, Eli Lilly and Company, Gilead Sciences Inc., Boehringer Ingelheim International GmbH., Amgen Inc., Allergan Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Ipsen Pharma S.A., Hikma Pharmaceuticals PLC, Lupin Ltd., Recordati S.p.A., Ionis Pharmaceuticals Inc., Amryt Pharma plc , Strongbridge Biopharma PLC, Aquestive Therapeutics Inc., Peptron Inc., Crinetics Pharmaceuticals, Chiasma Inc.

North America was the largest region in the acromegaly market in 2023. The regions covered in acromegaly report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the acromegaly market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, and Spain.

The primary classifications of acromegaly encompass ectopic acromegaly and acromegaly due to growth hormone. Ectopic acromegaly is a rare medical condition characterized by the overproduction of growth hormone (GH) originating from a source outside the pituitary gland. The diagnostic methods employed include GH and IGF-I measurement, growth hormone suppression tests, imaging, and various others, which can be administered through diverse routes, including oral, parenteral, and others. Treatment options are available, ranging from medications, somatostatin analogues, dopamine agonists, and growth hormone antagonists to surgical procedures, radiation therapy, and other approaches. These treatments find application across various end users, including hospitals, specialty clinics, homecare settings, and others.

This report provides acromegaly market statistics, including acromegaly industry global market size, regional shares, competitors with an acromegaly market share, detailed acromegaly market segments, market trends and opportunities and any further data you may need to thrive in the acromegaly industry. This acromegaly market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The acromegaly market consists of revenues earned by entities by providing hormone replacement therapy, pituitary radiotherapy and lifestyle modifications. The market value includes the value of related goods sold by the service provider or included within the service offering. The acromegaly market also includes sales of octreotide, lanreotide and somavert. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.